Taproot Management’s AstraZeneca AZN Stock Holding History

Taproot Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,998	Closed	-$6.43M	–	185
2025 Q4	$6.43M	Buy	+34,998	New	+$6.14M	1.04%	33

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Taproot Management's AZN Position: Q1 2026 in Review

Taproot Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 34,998 shares — an estimated $6.43M sold.

Taproot Management first reported a position in AZN in Q4 2025 and held it in 1 quarter. The position peaked at $6.43M in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Taproot Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Taproot Management sold 34,998 AstraZeneca shares in Q1 2026, an estimated $6.43M.
Taproot Management first reported a position in AstraZeneca in Q4 2025 and held it in 1 quarter.
Taproot Management's AstraZeneca position peaked at $6.43M in Q4 2025.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Taproot Management's 13F filing for Q1 2026, filed 13 May 2026.